Apart from improvements in multiple cardiometabolic risk factors, tirzepatide also improves various obesity-related complications such as obstructive sleep apnoea (OSA), metabolic dysfunction-associated steatohepatitis (MASH) and heart failure with preserved ejection fraction [28,29,30]
In January 2023, Versanis launched a phase 2b human trial of bimagrumab as an obesity treatment, either alone or co-administered with semaglutide, Novo Nordisks GLP-1 agonist
Safety concerns, as payers hesitate due to limited long-term data and uncertainty about optimal treatment duration
Another ASCO study, conducted by the Cleveland Clinic, examined records of more than 12,000 people who had diverse types of stage 1, 2, or 3 cancer
Recent Findings Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have revolutionized the treatment of diabetes and obesity and are increasingly being identified as promising therapies for a wide range of conditions